Eli Lilly's GLP-1 growth is only getting started as Novo Nordisk braces for a decline in 2026
Eli Lilly's expanding GLP-1 portfolio and robust sales approach enhance its competitive stance in the obesity market, potentially driving significant...
Read Full Article →